

Partnering in Cardiometabolic Diseases



Boehringer Ingelheim’s cardiometabolic research strategy takes a holistic view of the broader therapeutic needs of patients who may often have multiple conditions, connected by underlying similar pathologies. Our innovation in cardiometabolic diseases is evidenced through our long history of excellence in research and landmark clinical trials, culminating in our most recent breakthrough treatments in type 2 diabetes, anticoagulation and heart failure care.

Inspired by patients, we believe that by working together with our global community of partners, we can bring critical diversity to innovation and accelerate the next breakthroughs that will transform lives now, and in generations to come.


Partnering Interests

- New therapeutic concepts with strong human disease link
- Anti-inflammatory concepts in NASH
- Control of aberrant tissue remodeling and fibrosis in NASH
- Hepatoprotective and regenerative approaches
- Targeting energy expenditure and muscle mass for obesity
- Control of food intake with superior tolerability to standard of care
- Innovative concepts for heart failure, stroke and other CV specialty care indications

Modalities: NBEs, NCEs and oligonucleotides

Disease Area Focus

- Non-alcoholic steatohepatitis stage 4
- Obesity
- CV specialty care indications



Clinical Portfolio

PHASE 1	PHASE 2	PHASE 3
Food intake regulator*	GLP1/GCGR agonist*	Empagliflozin**
GLP1/FGF21 agonist*	GLP1/GCGR agonist*	Empagliflozin**
Heart disease modulator*	sGC activator	
Transient receptor potential channel inhibitor*	SGLT2 inhibitor + aldosterone synthase inhibitor	

* Partnered projects or acquired assets
** New indication

Therapeutic Area Portfolio and Facts

170 scientists based in USA and Germany

12 clinical-stage programs

14 currently-marketed products in cardiovascular and metabolic disease indications

Our Partners



Meet the Team



Manuel Baader
manuel.baader@boehringer-ingelheim.com



Andrew Whittle
andrew.whittle@boehringer-ingelheim.com



Robert Augustin
robert.augustin@boehringer-ingelheim.com



Peter Benz
peter_michael.benz@boehringer-ingelheim.com